// App-Quantinova.ai

: Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observational Studies

Researchers

Presenter

  • Bin Li

Principal Investigators

  • Kaili Ren

  • Lei Shen

  • Peijie Hou

  • Zhenqiang Su

  • Alessandra Di Bacco

  • Jin-Liern Hong

  • Aaron Galaznik

  • Ajeeta B Dash

  • Victoria Crossland

  • Paul Dolin

  • Sandor Szalma

Medical Centers

  • Observational Res Analytics, Data Science Institute, Takeda Pharmaceuticals International Co., Cambridge, MA

  • Observational Res Analytics, Data Science Institute, Takeda Pharmaceuticals International Co., Cambridge, MA

  • Observational Res Analytics, Data Science Institute, Takeda Pharmaceuticals International Co., Cambridge, MA

  • Takeda Pharmaceuticals International Co., Cambridge, MA

  • Global Outcomes Research, Data Science Institute, Takeda Pharmaceuticals International Co., Cambridge, MA

  • Epidemiology, Takeda Pharmaceuticals International Co., London, United Kingdom

  • Observational Res Analytics, Data Science Institute, Takeda Pharmaceuticals International Co., Cambridge, MA

Locations

  • United States

  • United Kingdom

Companies

  • Takeda Pharmaceutica

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • carfilzomib Intravenous

  • Bortezomib

Outcome

  • N/A

Study Design

  • Observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved